Analysts Anticipate ESSA Pharma Inc. (EPIX) to Post -$0.18 EPS

Wall Street brokerages predict that ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) will report ($0.18) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings per share of ($0.19) in the same quarter last year, which would suggest a positive year over year growth rate of 5.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, December 13th.

On average, analysts expect that ESSA Pharma will report full year earnings of ($0.55) per share for the current year, with EPS estimates ranging from ($0.62) to ($0.49). For the next year, analysts forecast that the firm will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.68) to ($0.57). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for ESSA Pharma.

A number of research firms recently issued reports on EPIX. Zacks Investment Research upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research report on Monday, September 11th. Dawson James reiterated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. Finally, Bloom Burton cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $4.75.

COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate ESSA Pharma Inc. (EPIX) to Post -$0.18 EPS” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at

ESSA Pharma (EPIX) opened at $0.26 on Wednesday. ESSA Pharma has a 12-month low of $0.25 and a 12-month high of $3.59. The company has a debt-to-equity ratio of -3.00, a current ratio of 2.32 and a quick ratio of 2.32.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with's FREE daily email newsletter.

Leave a Reply